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Summary: A number of “interesting” risk markers have been proposed as providing prognostic informations in acute 
coronary syndromes (ACS). Elevation in plasma inﬂ  ammatory and necrosis biomarkers have been related to future cardio-
vascular events in individuals with or without prior myocardial infarction. Recently BNP and pro-BNP are entered in 
clinical practice to recognize patients at major risk, providing incremental information respect to the traditional markers. 
Together with these laboratory indexes, a few of promising laboratory markers once easily available, could become usefull 
in identiﬁ  cation of patients at high risk.
Several studies evaluated many markers of platelet aggregation, endothelial dysfunction and vascular thrombosis, but 
it is not yet clear whether each of the proposed markers may provide incremental predictive information.
We describe, following the most studies reported in literature, the laboratory markers with potential clinical and prog-
nostic power that could early help physicians in the identiﬁ  cation of patients with impaired coronary disease and more 
narrowed coronary arteries.
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Introduction
Acute coronary syndromes without ST elevation (ACS) are heterogeneous disorders ranging from 
unstable angina pectoris (UA) without evidence of myocardial necrosis to myocardial infarction (MI) 
associated with a signiﬁ  cant increase of troponin and isoenzime MB creatinkinase.
1
Because of heterogeneous clinical presentation, ACS encompasses a wide range of events and different 
prognosis in relation to plaque type lesions and coronaric atherosclerosis diffusion. Risk assessment is 
based on clinical history and examination, electrocardiographic (ECG) characteristics and markers of 
myocardial damage, but it remains relatively inaccurate. 
Recently, several biomarkers have been purposed to identify patients at high risk needing for more 
aggressive therapy or early angiography, to detect their risk proﬁ  le and optimise the treatment.
2 Biomarkers 
can provide three types of information in patients with ACS: ﬁ  rst, they may be useful for the immediate 
diagnosis of disease; secondly, they can assist in risk stratiﬁ  cation; thirdly, a biomarker can direct thera-
peutic decisions by monitoring course of disease and giving some prognostic informations.
In this report we review, on the basis of more recent literature, the biomarkers with potential
clinical and prognostic signiﬁ  cance able to recognize patients with more advanced coronary
disease; therefore, we describe the eventual possibility to identify, by laboratory research at hospital
admission, patients candidates for angiographic study that would more beneﬁ  t from aggressive
behaviour. (ﬁ  gure 1)
Pathogenesis of ACS
Advances in understanding of coronary disease have focused attention on the plaque composition rather 
than degree of stenosis; non stenotic lesions are more frequently implied in ACS, nonocclusive plaques 
may become complicated by thrombus and rapidly progress to total occlusion. Five principal causes of 
ACS habe been described, they include: 1) plaque rupture with acute thrombosis by formation of blood 
clot that gradually occludes the lumen, the pivotal event in the atherothrombotic process; 2) mechanical 
obstruction due to progressive increase of plaque volume; 3) inﬂ  ammation, by local and sistemic produc-
tion of mediators as cytokines growth factors and enzymes that activate the plaque and disrupt the 
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ﬁ  brous cap; 4) dynamic obstruction inﬂ  uenced by 
endothelial dysfunction leading to coronary vaso-
costriction; 5) plaque embolization at distant level 
from atherothrombotic coronary occlusion.
3,4 It is 
rare that any of these contributors exists in isola-
tion. However, clinical presentation of ACS may 
vary substantially with respect to the mixture of 
contributions from each of these major mecha-
nisms and patients are likely to benefit from 
different therapeutic strategies. The risk of subse-
quent death and/or recurrent ischemic events 
among patients with ACS also varies widely, 
depending on the presence or absence of irrevers-
ible myocyte injury, the hemodynamic conse-
quences of ischemia and/or infarction, and the 
extent of atherosclerotic vascular disease.
5
Traditional cardiac risk factors that predispose 
to atherosclerosis are only a part of the equation 
and must be considered within the setting of other 
systemic and local contributors that may adversely 
affect coronary plaque progression and thrombotic 
complication. The efforts must be addressed in 
early detection of culprit plaque, by more sensitive 
serum markers assessment to ﬁ  nd and treat the 
vulnerable patients at elevated risk.
Traditional Risk Markers
Recently AHA/ACC have purposed a TIMI risk 
score for identiﬁ  cation of patients with major risk, 
however this classiﬁ  cation is not completely able 
to identify all high risk subjects. Hence, the intro-
duction of other markers easily available could 
bring to worth a better risk proﬁ  le evaluation.
6
Classical cardiac markers usually considered as 
strong predictors among patients with coronary 
disease, are Troponin T (TnT) and C-reactive 
Protein (CRP), both related to increased risk of 
recurrent ischemic events and cardiovascular 
death.
Elevated TnT levels appear related to more 
‘active’ lesions, which in turn are associated with 
increased long-term coronary instability. Angio-
graphic studies have shown an association between 
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Figure 1. Traditional and novel laboratory risk markers and their potential clinical signiﬁ  cance.
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increased troponin levels and complex lesions, 
more severe coronary artery disease, decreased 
coronary blood ﬂ  ow and greater activation of the 
coagulation system compared to patients with 
normal troponin levels.
7
Recently, a substudy from GUSTO-IV clearly 
demonstrated that TnT is associated with early and 
late risk of mortality and myocardial infarction, 
probably due to greater microembolization risk or 
to major extension of coronary atherosclerosis.
8 
Hence, the persistence of increased risk over
time may reflect more severe disease with
greater likelihood of continued coronary plaques
instability.
The correlation between elevated CRP levels 
and prognosis in coronary disease may be mediated 
by the vascular effects of proinﬂ  ammatory cyto-
kines, including tumor necrosis factor TNF-α, 
interleukin IL-1 and IL-6, which induce the hepatic 
production of CRP.
9 Mononuclear cells of patients 
with recurrent unstable angina show an enhanced 
production of IL-6 in response to low-dose of 
lipopolysaccharide (LPS), correlated with baseline 
CRP levels, six months after the last acute event: 
this persisting acute-phase responsiveness could 
explain the association between CRP and acute 
coronary events.
10
Some works have indicated that the protein 
doesn’t reﬂ  ect only inﬂ  ammation stage that concur 
to atherosclerotic process, but it could have a 
direct role in the plaque rupture: unstable athero-
sclerotic plaques have an increased number of 
macrophages that seem to be most abundant in the 
vulnerable shoulder region of the ﬁ  brous cap, 
overlying the core of atheroma within the vessel 
wall.
11 The pronounced elevation of CRP is tran-
sient and likely related to an acute-phase reaction. 
Some patients with ACS might have a hyper-
responsiveness of the inﬂ  ammatory system, which 
might exaggerate the acute-phase reaction and 
increase the immune system reaction. Such 
mechanism is supported by the observations of 
co-localization of CRP and activated complement 
in infarct-related myocardium. It has been shown 
that CRP also stimulates production of tissue 
factor by mononuclear cells, the main initiator of 
blood coagulation.
12
CRP increase appears related to incidence of 
revascularization in patients with ACS and 
increased risk of recurrent ischemia. However, 
studies are not in accordance: Toss et al. recruited 
no correlation; on the other hand, Liuzzo et al. 
showed worse prognosis in patients with UA.
13,14 
Moreover, ECAT Angina Pectoris Study showed 
that elevated CRP levels highly correlate with low 
left ventricular ejection fraction.
15
The highest values in CRP have been found in 
patients with the largest increase in troponin 
concentrations. High CRP levels are independent 
predictors of death in these patients, but are not 
associated with a greater risk of MI. These appar-
ently contradictory ﬁ  ndings may be explained by 
hypothesizing a strong inﬂ  uence of troponin values 
on CRP increase in ACS.
16
B-Type Natriuretic Peptide
as Additional Risk Marker
Many studies have been shown that elevation of 
BNP as well as NT-proBNP levels obtained after 
the acute phase (median, 40 to 72 hours after 
symptoms onset) in patients with a broad range of 
ACS independently predicts mortality.
17–19 
However, in most of the reports, authors do not 
distinguish subjects with low ejection fraction and 
LV enlargement; in all studies, BNP levels appear 
related to increase of heart failure, predicting of 
cardiac remodeling and pump dysfunction. 
Recently, BNP has been related with coronary 
vessels involvement showing a signiﬁ  cant correla-
tion with left descending artery disease and TIMI 
ﬂ  ow.
20 In another report, BNP appeared associated 
with multivessels disease in ACS patients without 
systolic dysfunction.
21
Data from both experimental and clinical 
studies suggest that the plasma levels of BNP may 
reﬂ  ect the size or severity of ischemic insult, even 
in absence of myocardial necrosis. Speciﬁ  cally, in 
human models of ischemia, BNP levels have been 
shown to increase transiently both after exercise 
in patients with stable coronary disease and after 
uncomplicated coronary angioplasty, despite stable 
intracardiac filling pressures.
22,23 Others have 
shown the rise in the level of BNP is correlated 
with the size of an ischemic territory during nuclear 
stress imaging.
24
All these data suggest that BNP could represent 
not only a marker of LV enlargement but also a 
marker of coronary disease extension: BNP could 
increase during ischemic damage in patients with 
CAD, suggesting that elevated levels are associated 
with larger extent as well as greater severity of 
ischemia, independently on LV systolic dysfunction. 
(ﬁ  gure 1)
Biomarker Insights 2006:1126
Palazzuoli et al
Biomarkers of Platelet Activation
Biomarkers of platelet activation may provide clues 
regarding the extent of platelet activation in patients 
with ACS and predict the severity of the inﬂ  amma-
tory response. Rupture or erosion of an atheroma-
tous plaque exposes subendothelial proteins such as 
collagen and von Willebrand factor, leading to adhe-
sion via the platelets surface receptors. This adhe-
sion causes platelet activation which triggers a 
conformational change in the platelet glycoprotein 
IIb/IIIa receptor and generates the enzyme thrombin 
from circulating prothrombin which converts 
ﬁ  brinogen to ﬁ  brin. Fibrin and von Willebrand factor 
bind to the GP IIb/IIIa receptor and trap multiple 
activated platelets leading to their aggregation.
Soluble CD40 ligand is a transmembrane glyco-
protein of the tumor necrosis factor family. CD40L 
has been shown to promote atherosclerosis and 
plaque instability,
25 to retain inﬂ  ammatory effects 
through promotion of platelet-monocyte aggre-
gates and production of reactive oxygen species.
26 
In addition to inﬂ  ammatory properties, platelet 
CD40L stabilizes platelet-platelet aggregates, 
target of numerous antiplatelet agents used in the 
treatment of ACS.
27
In patients with ACS, sCD40L identifies a 
subgroup at increased 6-month risk of death or 
non-fatal MI.
28 The (OPUS)-TIMI 16 trial has 
shown that sCD40L provides prognostic ability 
independent of TnI or C-reactive protein.
29 These 
results conﬁ  rmed that ACS patients with elevated 
sCD40L are at higher risk of adverse coronary 
events relative to patients with ACS and no eleva-
tion of sCD40L.
P-selectin is a transmembrane cell adhesion 
molecule stored in endothelial cells and in platelet 
granules. Endothelial cell P-selectin mediates 
tethering and rolling of leukocytes along the acti-
vated endothelium, whereas platelet P-selectin 
mediates formation of platelet aggregates in pulsa-
tile high-shear stress conditions.
30 The majority of 
soluble P-selectin appears to be derived from 
platelets, because soluble P-selectin levels are 
correlated with established platelet markers but not 
with endothelial markers.
Attempts to use plasma P-selectin for risk 
stratification in ACS have yielded conflicting 
results. Some studies have suggested that P-selectin 
may be useful in risk stratiﬁ  cation for patients 
presenting with chest pain;
31 Yazici et al. have 
recently demonstrated a straight correlation 
between P-selectin and troponin suggesting a 
speciﬁ  c role of increased coagulation and myocar-
dial injury. Given its possible pathophysiological 
role in platelet aggregation and thrombosis,
P-selectin remains a possible therapeutic target.
32
Tissue plasminogen activator (t-PA) is a glyco-
protein produced mainly by vascular endothelial 
cells.
33, 34 It activates clot dissolution in the
presence of ﬁ  brin by conversion of plasminogen 
to plasmin, thereby cleaving cross-linked ﬁ  brin 
to D-dimer and other degradation products and 
it may also be involved in coronary plaque 
rupture.
35
A combined analysis of studies evaluating t-PA 
in coronary diseases, adjusted for some risk factors, 
suggests that CHD risk is about 50% greater in 
those with increased levels: a comparison of those 
in the top third with those in the bottom third of 
baseline t-PA antigen values yielded an odds ratio 
for CHD of 2.20 (1.70 – 2.85; 21 = 36) after adjust-
ment for age and town only, and of 1.48 (1.09 – 
2.01; 21 = 6) after further adjustment for classical 
CHD risk factors.
36, 37 
Epidemiological studies of t-PA antigen consis-
tently show strong correlations with PAI-1 activity 
or antigen.
38 This association may reﬂ  ect simulta-
neous release from endothelial cells, delayed
clearance of t-PA-PAI-1 complexes, acute-phase 
reactions, or mutual correlations during early and 
late phases of atherosclerosis.
39 
What is the potential biological signiﬁ  cance of 
the positive association between circulating t-PA 
antigen and risk is still unknown: t-PA is released 
from vascular endothelium, hence increased circu-
lating levels may be a marker of endothelial distur-
bance. In one study, circulating t-PA antigen 
correlated strongly with circulating levels of von 
Willebrand factor (vWF), another endothelial 
release product, as well as with risk markers asso-
ciated with endothelial dysfunction. Tissue plas-
minogen activator and PAI-1 may partly reﬂ  ect 
their mutual association with the inﬂ  ammatory 
response. While increased circulating free t-PA 
might increase ﬁ  brin lysis, no signiﬁ  cant associa-
tion of t-PA antigen was observed with ﬁ  brin D-
dimer levels.
40 ( ﬁ  gure 2)
Future Potential Markers
Metalloproteinases (MMPs) are zinc-dependent 
endoproteases with collagenase and/or gelatinase 
activity. Degradation of collagen ﬁ  brils compro-
mises plaque stability and the integrity of the 
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endothelial basament membrane, predisposing 
advanced atheromas to rupture.
41
There are many types of MMPs, the most known 
are MMP-2, a gelatinase capably to degrade type 
IV collagen, represented in the subendothelial 
basement membrane. MMP-8 is a collagenase 
produced by neutrophils, but also by endothelial 
cells, smooth muscle cells and macrophages in 
plaques. MMP-9 is a gelatinase widely implicated 
in ventricular remodeling and the development of 
heart failure.
42 MMPs are higly expressed in 
atheroslerotic plaques and subjects with acute 
coronary syndrome (ACS) have increased plasma 
levels of MMP-1, -2 and -9.
Some groups have found that MMP-1, -2 and 
-9 are not elevated at the presentation, but that
they increase during the subsequent 7 to 14 days.
43 
Other groups have reported no signiﬁ  cant elevation 
in MMP-2, but a rapid rise and fall of MMP-9 
within the ﬁ  rst week after ACS. Some authors 
measured MMP-8 concentrations in 181 patients 
positive for coronary artery disease (CAD) after 
angiography and they found that these subjects had 
higher MMP-8 concentrations, compared with 
patients without CAD, increasing with the number 
of stenotic vessels.
44
Another study reports an association between 
MMP levels during ACS and cardiovascular 
outcomes. In a study of 24 patients with ACS, 
elevation in MMP-1 at 7 and 14 days after ACS 
were negatively correlated with left ventricular 
ejection fraction.
45 Thus, the slow elevation of 
MMP levels after ACS and the lack of clinical 
outcome data do not currently make MMPs useful 
biomarkers in ACS.
It has recently recognized that polymorpho-
nuclear neutrophils (PMNs) are critical mediators 
in ACS, because of their recruitment and activation 
before platelet aggregation.
46 One of the principal 
mediators secreted on PMN activation is myelo-
peroxidase (MPO), a hemoproteine that is a
microbicidal enzyme, but it has also potent proath-
erogenic properties: infact, MPO can oxidize LDL 
cholesterol, ampliﬁ  cating uptake by macrophages 
and perpetuating foam cell formation.
47 Moreover, 
MPO promotes activation of metalloproteinases 
and destabilization and rupture of atherosclerotic 
plaques surface.
48 Furthermore, MPO catalytically 
consumes endothelium-derived nitric oxide, 
reducing its bioavailability and impairing
its vasodilatory and anti-inflammatory 
functions.
49
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Figure 2. Biomarkers of endothelial dysfunction and their speciﬁ  c actions in atherosclerotic process. 
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Elevated MPO plasma levels in patients with 
unstable angina and acute myocardial infarction 
have been shown. Biasucci et al. demonstrated that 
neutrophils are activated in acute coronary 
syndromes, may be not only secondary to isch-
emia-reperfusion injury.
50
Some authors found that MPO serum levels 
were equally distributed among patients with low 
and high Troponin T (TnT) serum levels, which 
indicates that elevated MPO levels are not tempo-
rary related to myocardial injury.
47 Moreover, MPO 
identiﬁ  es patients at risk for cardiovascular events 
who have low baseline TnT levels, even before 
complete microvascular obstruction. In patients 
with low CRP levels, MPO identiﬁ  es those with 
increased risk for cardiovascular events. These data 
suggest that recruitment and degranulation of 
PMNs is a primary event and is followed by release 
of other systemic mediators and acute-phase 
proteins such as CRP.
46,49
Pregnancy-associated plasma protein A (PAPP-A) 
is a peptide speciﬁ  cally elevated in pregnancy, 
specially in the ﬁ  rst trimester and it is used for the 
screening of chromosomal abnormalities. PAPP-A 
is a zinc-binding metalloprotease that indirectly 
activates insuline-like growth factor (IGF), a potent 
mitogen and chemotactic agent for vascular smooth 
muscle cells. Because inhibition of IGF signaling 
has been shown to delay atherosclerosis, it is 
possible that PAPP-A indirectly promotes athero-
sclerosis or restenosis by increasing the activity of 
IGF. Infact, PAPP-A levels after angioplasty have 
been implicated as a possible mechanism for reste-
nosis.
51
In the same study has been found that PAPP-A 
was not associated with TnT or creatine-kinase-MB 
elevation, suggesting that PAPP-A is not useful for 
detectable myocardial infarction, though it may 
have diagnostic value for identifying patients with 
ACS. Other studies would conﬁ  rm the hypothesis 
that PAPP-A is an independent predictor of cardio-
vascular events, regardless of troponin status.
52,53
These studies suggest that PAPP-A may deﬁ  ne 
subsequent cardiovascular risk in patients with 
unstable angina and no troponin elevation. More-
over, increased serum levels of PAPP-A may reﬂ  ect 
instability of atherosclerotic plaques.
54
In the last few years, several studies demon-
strated that raised levels of interleukin-6 are 
common in unstable angina, correlate with C-reac-
tive protein, and are associated with prognosis, 
thus conﬁ  rming the importance of the cytokine 
pathway for the production by the liver of acute-
phase proteins and strengthening the importance 
of inﬂ  ammation in this syndrome. Therefore, inter-
leukin (IL)-18, originally identiﬁ  ed as an interferon 
(IFN)-γ-inducing factor in Kupffer cells and 
macrophages, has been proved to play a central 
role in the inﬂ  ammatory cascade. Furthermore, 
IL-18 acts in synergy with IL-12 to promote the 
development of T helper 1 responses.
55 Recently, 
increased IL-18 expression has been reported in 
human atherosclerotic plaque, mediating INF-γ 
release locally. Moreover, animal models support 
the proatherogenic role of IL-18 as well as the 
beneﬁ  cial effect of inhibiting IL-18 on plaque 
progression and composition. Thus, serum IL-18 
level has been recently identiﬁ  ed as a strong inde-
pendent predictor of death from cardiovascular 
causes in patients with coronary artery disease 
regardless of the clinical status at admission. This 
result strongly supports recent experimental 
evidence of IL-18-mediated inﬂ  ammation leading 
to acceleration and vulnerability of atherosclerotic 
plaques.
56
The ST2 gene is a member of the interleukin-1 
receptor host defense-inﬂ  ammation family. The 
protein product of ST2 encodes a transmembrane 
receptor form (ST2L) and a truncated soluble 
receptor form (ST2) that can be detected in human 
serum. It is known that ST2 directs Th2 lympho-
cyte function; this ﬁ  nding suggests that ST2 is 
induced in conditions of myocardial overload such 
as myocardial infarction, when the remaining 
viable myocardium must bear more stress. Indeed, 
soluble ST2 levels are increased in the serum of 
patients one day after myocardial infarction. 
Furthermore, ST2 serum levels predict outcome in 
patients with heart failure, and a change in ST2 
over time is also associated with prognosis.
57 These 
data suggest that serum levels of the interleukin-1 
receptor family member ST2 predict mortality and 
heart failure in patients with acute myocardial 
infarction.
58
Conclusions
Several emerging laboratory markers are now 
disposal for diagnosis and prognosis of ACS. Some 
common parameters are actually recommended for 
risk stratiﬁ  cation (Troponine, CRP and BNP or 
pro-BNP), some others could become important 
to identify patients at higher risk: the more prom-
ising seem to be parameters of platelet activation
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(P-selectin and t-PA) and inﬂ  ammatory markers 
mediators (MPO) (ﬁ  gure 1).
Every cited markers could represent a speciﬁ  c 
index of atherosclerotic process and plaque activa-
tion, physicians effort could address in the discover 
and identiﬁ  cation of laboratory parameters with 
both easy sample and clinical signiﬁ  cance applica-
tion. The combination approach could permit in 
the future to encompass from the laboratory to the 
clinical aspects and to recognize patients with more 
dangerous coronary lesions and coronary disease 
severity.
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